Navigation Links
Study finds cisplatin less effective than standard treatment for patients with anal cancer
Date:4/22/2008

HOUSTON - When administered before chemoradiation, the common anti-cancer drug cisplatin neither improved disease-free survival nor reduced the number of colostomies needed when compared to the standard treatment for patients with anal canal cancer, according to a study published in the April 23 issue of the Journal of the American Medical Association.

In the largest cooperative phase III randomized controlled trial of its kind, a multicenter research team led by Jaffer Ajani, M.D., professor in the Department of Gastrointestinal Medical Oncology at The University of Texas M. D. Anderson Cancer Center, compared the standard treatment regimen of fluorouracil plus mitomycin and radiotherapy to fluorouracil plus cisplatin and radiotherapy in 644 patients with anal canal cancer. The five-year disease-free survival rate was 60 percent in the mitomycin-based group and 54 percent in the cisplatin-based group. The five-year overall survival rate was 75 percent in patients receiving mitomycin versus 70 percent receiving cisplatin, with more cancer-related deaths in the cisplatin-based group (54 patients) compared to mitomycin-based group (28 patients).

Patients who received cisplatin-based treatment resulted in significantly higher rates of colostomy (19 percent versus 10 percent). It is widely held among practicing oncologists that the colostomy procedure, which creates an alternative exit from the colon to divert waste, should only be used as a last resort in the treatment of anal canal cancer due to its considerable affect on the patient's quality of life.

"Based on preliminary data from smaller trials that suggested considerable sensitivity to the fluorouracil plus cisplatin combination, cisplatin has gained popularity among oncologists as a drug to treat anal canal cancer," said Ajani. "However, it is clear from this data that cisplatin is not the drug to use and its use should be discontinued in standard therapy."

The study expanded on findings from two pilot studies that encouraged oncologists to believe that cisplatin could potentially be used to reduce the cancer in the primary tumor and lymph nodes prior to administration of concurrent chemoradiation. The research group hypothesized that using cisplatin to downsize the tumors first could be an effective strategy for treating the disease because previous studies have established that chemoradiation is more effective for smaller anal canal carcinomas than larger ones.

"There have been incremental advancements in the treatment for anal canal cancer in the last decade and there was hope that the unique cisplatin-based strategy would offer an improved, less-toxic therapy to patients suffering from the disease," Ajani said. "While our research did not uncover a new standard of treatment, comparative studies such as this one are imperative to determining best practices and informing community oncologists."

According to the American Cancer Society, an estimated 5,070 new cases of anal canal cancer will be diagnosed in 2008. The five-year disease-free survival of approximately 65 percent has not improved since the early 1990s. Primary anal canal tumor size has a direct bearing on cure rates, and the five-year survival rates decrease significantly for tumors larger than 5 cm diameter. Approximately 25 percent of newly diagnosed anal carcinomas are larger than 5 cm in diameter.

From this study, it is anticipated that researchers will look to explore other options such as newer targeted therapies and intensity-modulated radiation plus concurrent chemotherapy to improve disease-free and colostomy-free survival relative to the continued standard of concurrent chemoradiation with fluorouracil and mitomycin.


'/>"/>

Contact: Robyn Stein
robyn.stein@gabbe.com
212-220-4444
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. Potential viral therapy weapon for difficult cancers is safe and effective in study
2. Study: Counseling trauma victims causes secondary trauma
3. Rat study suggests why teens get hooked on cocaine more easily than adults
4. Study Shows Increased Out-of-Pocket Expenses May Negatively Influence Initiation of TNF Blocker Therapy
5. Teenage suicides: Study advocates greater family support
6. Cancer cells spread by releasing bubbles, according to an MUHC study
7. Many Cancer Survivors Are Overweight and Sedentary: Study
8. Cardicas C-Port Anastomosis Systems Facilitate Beating Heart Bypass Surgery in Study
9. Study reveals inaccuracies in studies of cancer treatment
10. Obesity, inactivity as common among cancer survivors as rest of Canadians, study shows
11. Choices Sap Your Stamina, Self Control: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Compliancy Group is ... software, The Guard®, has helped another long-time client pass their Department of Health ... satisfy the law. , Thanks to the help of the Compliancy Group's Audit ...
(Date:9/20/2017)... ... September 20, 2017 , ... The Centers for Medicare ... Rule that it will transition to using only Worksheet S-10 to distribute Disproportionate Share ... of three live 60-minute complimentary webinars on October 17, 2017 at 2 ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... for overcoming addiction. “RECYCLED Ezekiel's Plan for Freedom from ADDICTION” is the ... extensive background in the field of addiction and homeless services, including more than ...
(Date:9/20/2017)... ... ... “The Foggy Road to Moorwick”: the adventures of a young Scottish girl yearning to see ... Liston, a busy mother of five who used her time waiting for children to finish ... over twenty years. It was a way to give some meaning to the hours ...
(Date:9/19/2017)... ... September 19, 2017 , ... Only a few physicians ... include Brevard’s own Ross A. Clevens, MD, FACS . The founder and medical ... Plastic and Reconstructive Surgeon who trained at Yale, Harvard and the University of Michigan. ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... its meeting with the U.S. Food and Drug Administration ... At the meeting, ... for submission of ORMD-0801, would be a Biologics License ...
(Date:8/31/2017)... PM360,s annual Innovations Issue, published in ... innovations happening across the industry. Established six years ago, ... providing a comprehensive look at the newest and most ... innovative companies, startups, divisions, products, services, and strategies from ... "Everyone in this industry wants to do better—in all ...
(Date:8/28/2017)... Aesculight ®, a division of LightScalpel ®, LLC, is announcing its ... 20 years of American veterinary laser surgery innovation, Aesculight® is revolutionizing veterinary ... ... with his new VetScalpel laser. Dr. Duclos practices veterinary dermatology at the ... ...
Breaking Medicine Technology: